{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:58:38Z","timestamp":1648832318992},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.jcrc.2009.03.009","type":"journal-article","created":{"date-parts":[[2009,7,4]],"date-time":"2009-07-04T04:30:58Z","timestamp":1246681858000},"page":"590-594","source":"Crossref","is-referenced-by-count":0,"title":["Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?"],"prefix":"10.1016","volume":"24","author":[{"given":"David","family":"Ahishakiye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Lorent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gottignies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcrc.2009.03.009_bib1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib3","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1097\/01.CCM.0000085141.75513.2B","article-title":"Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland","volume":"31","author":"Padkin","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib6","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"Drotrecogin alfa [activated] for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jcrc.2009.03.009_bib8","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1097\/01.CCM.0000183002.26587.FF","article-title":"Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial","volume":"33","author":"Eichacker","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00134-007-0556-8","article-title":"Increasing evidence that the risks of rhAPC may outweigh its benefits","volume":"33","author":"Eichacker","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib10","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1097\/01.CCM.0000181729.46010.83","article-title":"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE","volume":"33","author":"Vincent","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib11","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc6879","article-title":"Drotrecogin alfa (activated): real-life use and outcomes for the UK","volume":"12","author":"Rowan","year":"2008","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2009.03.009_bib12","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/00003246-200111000-00003","article-title":"Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis","volume":"29","author":"Bernard","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s001340050863","article-title":"Application of SOFA score to trauma patients. Sequential organ failure assessment","volume":"25","author":"Antonelli","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s001340050931","article-title":"The use of maximum SOFA score to quantify organ dysfunction\/failure in intensive care. Results of a prospective, multicentre study","volume":"25","author":"Moreno","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s001340051316","article-title":"Evaluation of the SOFA score: a single centre experience of a medical intensive care unit in 303 consecutive patients with predominantly cardiovascular disorders","volume":"26","author":"Janssens","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2009.03.009_bib18","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","article-title":"Serial evaluation of the SOFA score to predict outcome","volume":"286","author":"Lopes Ferreira","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jcrc.2009.03.009_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcrc.2005.07.003","article-title":"Daily evaluation of organ function during renal replacement therapy in intensive care unit patients with acute renal failure","volume":"21","author":"Cappi","year":"2006","journal-title":"J Crit Care"},{"key":"10.1016\/j.jcrc.2009.03.009_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/cc2900","article-title":"Science review: extracellular acidosis and the immune response: clinical and physiologic implications","volume":"8","author":"Kellum","year":"2004","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2009.03.009_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1164\/ajrccm.159.2.9802093","article-title":"Acidosis stimulates nitric oxide production and lung damage in rats","volume":"159","author":"Pedoto","year":"1999","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944109000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944109000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T10:51:32Z","timestamp":1545130292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944109000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0883944109000793"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2009.03.009","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}